促红细胞生成素对胃癌相关性贫血患者的疗效  

Clinical effect of erythopoientin in the treatment of gastric cancer- associated anemia

作　　者：吴付兵[1] 王星[1] 王康霞[1] 王明元[1] 黄雯[1] 

机构地区：[1]南京军区福州总医院第一附属医院肿瘤中心,福建莆田351100

出　　处：《现代肿瘤医学》2015年第2期241-243,共3页Journal of Modern Oncology

基　　金：莆田市科技计划项目[编号:莆市科2012S02(1)]

摘　　要：目的:观察促红细胞生成素对胃癌相关性贫血患者疗效及预后的影响。方法:将60例胃癌晚期肿瘤相关性贫血患者按照随机分组的方法分为治疗组(30例)和对照组(30例),对照组采用常规化疗以及常规抗贫血治疗,治疗组采用常规化疗加重组人促红细胞生成素治疗,每次150U/kg,皮下注射3次/周,疗程8周,比较两组血红蛋白、红细胞和红细胞比容,评价疗效。结果:治疗组在使用重组人促红细胞生成素后的第4周和第8周,有效率为33%(10/30)和67%(20/30),对照组效率为10%(3/30)和17%(5/30);血红蛋白、红细胞和红细胞比容治疗组治疗前和治疗后4周相比较有极显著差异(P<0.01),治疗组治疗前和治疗后8周相比较有极显著差异(P<0.01),对照组治疗前和治疗后4周以及治疗后8周相比较没有差异。治疗组和对照组同期比较有极显著差异(P<0.01)。与治疗前比较,治疗组KPS评分较高,与对照组比较有显著差异(P<0.05)。结论:应用重组人EPO可以有效的治疗胃癌相关性贫血,改善患者贫血状态,临床效果良好,且无明显不良反应。Objective：To investigate the clinical effect of erythopoientin in the treatment of advanced gastric cancer-associated anemia.Method：All 60 gastric cancer patients in advanced stage were randomly divided into two groups：treatment group and control group.The therapeutic schedule of treatment group was routine chemotherapy combining with 150U/kg erythopoientin injection three times each week.The therapeutic schedule of control group was only routine chemotherapy.After 8 weeks of treatment,hemoglobin （Hb）,red blood cell （RBC） and hematocrit value （HCT） of the two groups were detected.Results：The effective rates of treatment group and control group after 4 weeks treatment were 33％ （10/30） and 10％ （3/30）,respectively.And the effective rate of treatment group and control group after 8 weeks of treatment was 67％ （20/30） and 17％ （5/30）,respectively.There were no obvious differences on treatment group after 4 and 8 weeks of treatment in Hb,RBC and HCT as compared with that of before receiving the treatment （P ＜ 0.01）.But there were no obvious differences on control group after 4 and 8 weeks of treatment in Hb,RBC and HCT as compared with that of before receiving the treatment.In addition,there were obvious differences between the two groups at the same period（P ＜ 0.01）.The KPS score of treatment group after treatment was higher than that before treatment and had difference compared with control group （P ＜ 0.05）.Conclusion：Hemopoietin has significant clinical effect on gastric cancer-associated anemia and does not have obvious toxic and side effect.

关 键 词：胃癌相关性贫血 促红细胞生成素 血红蛋白 红细胞 红细胞比容 

分 类 号：R735.2[医药卫生—肿瘤]